Kazia Therapeutics Limited (KZIA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$9.57−$0.2100 (−2.15%) on the dayAs of the close; data may be delayed.
KZIA price, last 12 months
Key stats
- Previous close
- $9.78
- Open
- $9.80
- Day range
- $9.42 – $9.99
- 52-week range
- $4.86 – $17.40
- Volume
- 227.1K
- Avg volume (20 days)
- 396.3K
- Market cap
- $148.8M
Performance
1W−7.9%
1M−34.5%
3M−32.7%
6M+31.8%
YTD+38.9%
1Y+21.5%
vs S&P 500, 1Y+4.7 pts
Technicals and fundamentals
About Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $148.8M